Table 3.
Patient characteristics in the external validation populations
| CPRD (n = 240 443) | SWEDEHEART (n = 67 428) | Nor-COAST (n = 497) | Bialystok PLUS/Polaspire (n = 219) | BACS/BAMI (n = 964) | Est BB (n = 12 986) | REACH (EU) (n = 18 100) | REACH (non-EU) (n = 28 407) | |
|---|---|---|---|---|---|---|---|---|
| Male sex | 149 433 (62%) | 50 062 (74%) | 306 (62%) | 167 (76%) | 735 (76%) | 5350 (41%) | 13 046 (72%) | 19 028 (67%) |
| Age (years) | 66 ± 9 | 62 ± 9 | 68 ± 9.5 | 65 ± 8 | 61 ± 12 | 63 ± 10 | 65 ± 9 | 67 ± 9 |
| Current smoker | 46 790 (19%) | 8681 (13%) | 62 (12%) | 41 (19%) | 134 (14%) | 2070 (16%) | 3307 (18%) | 4020 (14%) |
| Body mass index (kg/m2) | 28 ± 5 | 28 ± 5 | 27 ± 4 | 30 ± 5 | 29 ± 4 | 29 ± 4 | 28 ± 4 | 28 ± 6 |
| Systolic blood pressure (mmHg) | 139 ± 20 | 133 ± 20 | 139 ± 19 | 134 ± 20 | 135 ± 21 | 135 ± 18 | 141 ± 20 | 134 ± 19 |
| Diabetes mellitus | 38 346 (16%) | 17 690 (26%) | 97 (20%) | 64 (29%) | 232 (24%) | 2321 (18%) | 5749 (32%) | 11 955 (42%) |
| Coronary artery disease | 152 279 (63%) | 67 428 (100%) | 83 (17%) | 219 (100%) | 964 (100%) | 10 668 (82%) | 12 871 (71%) | 20 856 (73%) |
| Peripheral artery disease | 31 803 (13%) | 1142 (2%) | 38 (8%) | 21 (10%) | 36 (4%) | 1709 (14%) | 3681 (20%) | 3149 (11%) |
| Cerebrovascular disease | 71 853 (30%) | 3614 (5%) | 497 (100%) | 17 (8%) | 27 (3%) | 3314 (25%) | 5951 (33%) | 9385 (33%) |
| Abdominal aortic aneurysm | 6977 (3%) | 474 (1%) | 22 (4%) | 0 (0%) | 4 (0%) | 109 (0%) | 550 (3%) | 930 (3%) |
| Years since first CVD diagnosis | 0.5 (0.5–4.7) | 0.2 (0.1–0.2) | 2.0 (1.0–5.0) | 0.6 (0.5–0.9) | 4.8 (2.0–9.5) | |||
| Total cholesterol (mmol/L) | 4.7 (4.0–5.6) | 4.0 (3.4–4.7) | 3.9 (3.4–4.4) | 4.0 (3.3–4.7) | 3.9 (3.4–4.4) | 5.5 (4.8–6.4) | 5.2 (4.4–6.0) | 4.7 (4.0–5.4) |
| HDL-cholesterol (mmol/L) | 1.3 (1.1–1.6) | 1.1 (0.9–1.4) | 1.4 (1.1–1.7) | 1.2 (1.1–1.6) | 1.0 (0.9–1.2) | 1.3 (1.0–1.7) | ||
| LDL-cholesterol (mmol/L) | 2.1 (1.6–2.7) | 2.0 (1.6–2.5) | 2.2 (1.7–2.7) | 2.0 (1.7–2.4) | 3.1 (2.4–3.7) | |||
| Triglycerides (mmol/L) | 1.2 (1.0.9–1.7) | 1.2 (0.9–1.7) | 1.2 (0.8–1.7) | 2.6 (2.0–3.6) | 1.6 (1.1–2.2) | 1.5 (1.1–2.2) | ||
| Estimated GFR (mL/min/1.73 m2) | 67 ± 18 | 83 ± 19 | 78 ± 18 | 88 ± 21 | 78 ± 18 | 81 ± 19 | 73 ± 21 | 71 ± 23 |
| hsCRP (mg/dL) | 5.0 (2.0–9.0) | 1.8 (0.8–3.6) | 1.1 (0.5–2.5) | 1.8 (0.8–3.6) | 2.3 (1.1–5.0) | |||
| Statin | 65 075 (95%) | 434 (87%) | 231 (90%) | 914 (94.8%) | 4181 (32%) | 12 483 (69%) | 20 156 (71%) | |
| Antiplatelet therapy or anticoagulants | 179 129 (75%) | 67 049 (99%) | 448 (98%) | 211 (96%) | 902 (94%) | 12 646 (70%) | 20 831 (73%) | |
| Follow-up (years) | 5.3 (2.2–9.6) | 4.0 (1.8–6.9) | 2.2 (1.8–2.7) | 2.9 (2.5–3.5) | 4.7 (2.3–6.7) | 6.5 (0.7–9.9) | 1.9 (1.8–1.9) | 1.9 (1.5–1.9) |
| CVD events | 44 985 (19%) | 9270 (13%) | 54 (11%) | 20 (9%) | 130 (13%) | 3489 (39%) | 2201 (12%) | 2658 (9%) |
| Event rate per 1000 person-yearsa | 34 | 31 | 51 | 33 | 30 | 48 | 63 | 50 |
All data in n (%), mean ± standard deviation, or median (interquartile range). GFR, glomerular filtration rate (calculated with the Chronic Kidney Disease Epidemiology Collaboration formula); CVD, cardiovascular disease; hsCRP, high-sensitivity C-reactive protein.
a
Event rate of fatal + non-fatal (myocardial infarction, stroke) events per 1000 person-years.